Health Trials

HRD-negative Epithelial Ovarian Cancer

1

Review clinical trials related to HRD-negative Epithelial Ovarian Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated exploratory study designed to evaluate the safety, tolerability and preliminary efficacy of tumor neoantigen-pulsed autologous dendritic cell injection (YS247) in participants with HRD-negative epithelial ovarian cancer.

Participants needed: 9
Trial details
Age: 18-70Biological sex: FemaleType: InterventionalSponsor: Peking University Third HospitalUpdated: Mar 16, 2026
Eligibility criteria

Female aged 18-70 years (inclusive of cut-off values); body weight ≥45 kg. [+10]

(Per interview) Allergic diathesis with hypersensitivity to two or more drugs, o... [+17]

Read more